Massachusetts is the latest state going after insulin makers and the intermediaries officials accuse of price gouging. Why it ...

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...

That example, cited in a lawsuit Massachusetts Attorney General Andrea Campbell filed Jan. 13 against insulin manufacturers ...

Campbell’s lawsuit highlights the impact PBMs have on one drug. In Massachusetts, about 500,000 residents are living with diabetes, nearly all of whom rely on the daily use of insulin to survive.